A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL.
The file type is
Migraine is the second leading cause of disability in terms of 'years lived with disability' and it affects globally about 12% of the general population. Currently available preventive therapies are not specific to migraine. After the discovery of calcitonin gene-related peptide's (CGRP's) role in migraine pathophysiology, CGRP receptor antagonist drugs were developed specifically for migraine. Atogepant is the only oral, selective, potent, second-generation CGRP receptor antagonist approved indoi:10.18203/2319-2003.ijbcp20222154 fatcat:m7ljllwy3jg3di2equnuw42u6u